Gyros® AB, the leading provider of automated micro-immunoassays for the development of biotherapeutics, is pleased to announce the signing of an exclusive distribution agreement with SCRUM, a major supplier to the Japanese life-science market. Under the terms of the agreement, SCRUM will market, sell and fully support the Gyros product range, within the Japanese biopharmaceutical, contract research and contract manufacturing industries.
The Gyrolab® system from Gyros is increasingly being employed by leading biopharmaceutical companies, and their contracted service organizations, during drug development and clinical trials. The company’s success in Europe and the USA has encouraged its expansion into Asia-Pacific, where Japan is regarded as a major market.
"We are very happy to have such an experienced and well-established organization as SCRUM representing our products in the Japanese market", commented Erik Walldén, CEO and President of Gyros. "We believe that Japan represents a key market for us and that this agreement with SCRUM will lead to a significant expansion of our presence in the Asia-Pacific region.”
Mr. Takemitsu Furuta, Strategic Marketing Director of SCRUM commented, "The value of this revolutionary platform from Gyros has already been well recognized by many pharmaceutical companies and contract research organizations in Europe and the US. We anticipate a similar response in Japan, and are keen for the opportunity to introduce a technology that we strongly believe will facilitate studies and increase our customers’ efficiency. We are looking forward to the first official introduction at our exhibition stand during the upcoming 83rd Annual Meeting of the Japanese Pharmacological Society, in March, 2010."
For further information, please contact:
Erik Walldén, CEO
Tel: +46 18-56 64 00
Linda van Manen, BGA Group
Tel: +31 78 631 97 15
Notes to editors:
About Gyros AB
Gyros is the world leader in automated micro-immunoassays for therapeutic protein development.
Gyrolab, the company's automated and open platform, is a versatile analytical tool that dramatically reduces the time required to optimize and execute immunoassays. Time for assay optimization is cut from weeks, to a matter of days. This results in increased efficiency in process development and in clinical evaluation of therapeutic proteins. The ease of assay transfer is unsurpassed in the industry.
Gyrolab enables assays to be conducted with a significantly reduced background, four-log dynamic range and with higher throughput. All this is achieved using only nanoliter volumes of critical reagents and sample. More data can be generated in less time and with higher precision, consequently improving productivity and efficiency. Applications span the entire spectrum for immunoassays and Gyrolab is now firmly established as the preferred solution for pharmacokinetic (PK) assays in the development of therapeutic proteins.
Many major pharmaceutical companies and service providers - CMOs/CROs - have already implemented multiple Gyrolab platforms to boost their drug development process and to meet increasing regulatory demands on testing. Several validated assays are already in some phase of clinical sample analysis. Gyrolab xP complies with the requirements of 21 CFR part 11 and comprehensive validation support is provided.
The company has over 50 employees based at its headquarters in Uppsala, Sweden and at regional sales and support offices in the USA and Europe.
About SCRUM Inc.
SCRUM is a leading distributor instrumentation, equipment and reagents for life science market in Japan, with an established customer base. The company also provides a custom synthesis service for Peptides and Antibodies developed in its own laboratory.
Further information may be found at: www.scrum-net.co.jp
Contact: Takemitsu Furuta, Strategic Marketing Director firstname.lastname@example.org